99976-73-5

Basic information

• Product Name: Piperazinone, 1-cyclohexyl- (9CI)
• Synonyms: Piperazinone, 1-cyclohexyl- (9CI);1-cyclohexyl-2-piperazinone
• CAS NO: 99976-73-5
• Molecular Formula: C₁₀H₁₈N₂O
• Molecular Weight: 182.26272
• Product Categories: PIPERIDINE
• Mol File: 99976-73-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Piperazinone, 1-cyclohexyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazinone, 1-cyclohexyl- (9CI)(99976-73-5)
• EPA Substance Registry System: Piperazinone, 1-cyclohexyl- (9CI)(99976-73-5)

Safety Data

• Hazardous Substances Data: 99976-73-5(Hazardous Substances Data)

Upstream product

• 16817-90-6 2-amino-N-cyclohexylacetamide 
• 33952-53-3 cyclohexylcarbamoylmethylcarbamic acid t-butyl ester 
• 108-91-8 cyclohexylamine 

Downstream Products

• 1284243-18-0 4-{[3-chloro-6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-cyclohexyl-2-piperazinone 
• 1284246-66-7 4-{[3-chloro-6-(1-methylethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-cyclohexyl-2-piperazinone 
• 1284246-63-4 1-cyclohexyl-4-{[6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-2-piperazinone 

Relevant articles and documents

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.